Colorectal Cancer Clinical Trial
Official title:
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Verified date | May 2024 |
Source | Arcus Biosciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).
Status | Completed |
Enrollment | 44 |
Est. completion date | June 25, 2021 |
Est. primary completion date | January 27, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female participants = 18 years - Histologically confirmed gastroesophageal cancer or colorectal cancer that is metastatic, advanced or recurrent with progression - Participants for whom mFOLFOX is considered appropriate therapy - Must have at least 1 measurable lesion per RECIST v1.1. - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. - Must have received standard of care, including potentially curative available therapies or interventions. - Confirm that an archival tissue sample is available and = 24 months old; if not, a new biopsy of a tumor lesion must be obtained. - Adequate organ and marrow function - Previously treated central nervous system metastases, meeting the following criteria: - No evidence of progression by magnetic resonance imaging for at least 4 weeks prior to first dose. - Neurologic symptoms returned to baseline. - No immunosuppressive doses of systemic corticosteroids for at least 2 weeks before investigational product administration. - No carcinomatous meningitis. Exclusion Criteria: - Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product. - Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational product hazardous (eg interstitial lung disease, active infections requiring antibiotics, recent hospitalization with unresolved symptoms) or obscure the interpretation of toxicity determination or AEs, or concurrent medical condition requiring the use of immunosuppressive medications or immunosuppressive doses of systemic or absorbable topical corticosteroids. - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. - Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 30 days after the last dose of etrumadenant in combination with mFOLFOX. - Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy. - Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. - Participants with asthma who require intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections will not be excluded from this study. Participants on chronic systemic corticosteroids will be excluded from the study. - Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, breast, or prostate. - Prior chemotherapy, targeted small-molecule therapy, or radiation therapy within 4 weeks prior to Day 1 or has not recovered (ie, = Grade 1 or baseline) from AEs due to a previously administered agent, except = Grade 2 alopecia or = Grade 2 neuropathy and other AEs = Grade 2 considered not clinically significant by the Medical Monitor and Investigator. - Use of other investigational drugs (drugs not marketed for any indication) within 28 days of investigational product administration. |
Country | Name | City | State |
---|---|---|---|
Australia | Border Medical Oncology | Albury | New South Wales |
Australia | Chris O'Brien Lifehouse | Camperdown | New South Wales |
Australia | The Kinghorn Cancer Centre | Darlinghurst | New South Wales |
Australia | Peninsula & South Eastern Haematology and Oncology Group | Frankston | Victoria |
Australia | St. George Private Hospital | Kogarah | New South Wales |
Australia | Macquarie University Hospital | Macquarie Park | New South Wales |
Australia | Cabrini Hospital | Malvern | Victoria |
United States | Texas Oncology - Austin Midtown | Austin | Texas |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas |
United States | Rocky Mountain Cancer Centers | Denver | Colorado |
United States | Virginia Cancer Specialists, PC | Fairfax | Virginia |
United States | QUEST Research Institute | Farmington Hills | Michigan |
United States | Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas |
United States | Prisma Health | Greenville | South Carolina |
United States | Carolina BioOncology Institute | Huntersville | North Carolina |
United States | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | Maryland Oncology Hematology | Rockville | Maryland |
United States | Texas Oncology - San Antonio Medical Center | San Antonio | Texas |
United States | Texas Oncology - San Antonio Northeast | San Antonio | Texas |
United States | Arizona Clinical Research Center | Tucson | Arizona |
United States | Texas Oncology - Tyler | Tyler | Texas |
Lead Sponsor | Collaborator |
---|---|
Arcus Biosciences, Inc. |
United States, Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events (AEs) | From first dose date to 90 days after the last dose (Approximately 1 year) | ||
Primary | Incidence of dose-limiting toxicities (DLTs) during dose escalation phase | From first dose date to 28 days after the first dose | ||
Secondary | Plasma concentration of etrumadenant | Recorded at baseline (prior to first dose), during the first 4 cycles of treatment (2 months), at end of treatment and 30 days post end of treatment (i.e. in total approximately 3 months) | ||
Secondary | Percentage of participants with Objective Response as determined by Investigator according to RECIST v1.1 | From study enrolment until participation discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 3-5 years) | ||
Secondary | Percentage of participants with Disease Control (complete response, partial response, or stable disease) for > 6 months as determined by RECIST v1.1 | From study enrolment until disease progression or loss of clinical benefit (up to approximately 3-5 years) | ||
Secondary | Duration of Response as determined by the Investigator according to RECIST v1.1 | From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years) | ||
Secondary | Progression Free Survival (PFS) as determined by the Investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | From start of treatment up to first occurrence of progressive disease or death from any cause, whichever occurs first (up to approximately 3-5 years) | ||
Secondary | Overall Survival (OS) as determined by the Investigator according to RECIST v1.1 | From start of treatment up to death from any cause (up to approximately 3-5 years) | ||
Secondary | Receptor Occupancy in peripheral blood | Cycle 1 Day 1 through Cycle 4 Day 1 (2 months), at end of treatment and 30 days after end of treatment (in total approximately 3 months). Each Cycle is 14 days. | ||
Secondary | Immunomodulatory activity in subsets for AB928 in combination with mFOLFOX | Immunomodulatory activity will be assessed by aggregating data from biomarkers collected from peripheral blood samples | Cycle 1 Day 1 through Cycle 4 Day 1 (2 months), at end of treatment and 30 days after end of treatment (in total approximately 3 months). Each Cycle is 14 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |